However, a retrospective study of 100 patients with RA-ILD demonstrated that the anti-TNF-α therapy of adalimumab and infliximab should be used with caution in older patients with RA-ILD because lung complications can occur within months of initial anti-TNF-α treatment [79]. The gene discussed is TNF; the disease is interstitial lung disease.